Core Viewpoint - Baixinan-B (02185) experienced a significant stock price increase, rising nearly 15% towards the end of trading, with a current price of 6.14 HKD and a trading volume of 16.9358 million HKD, driven by recent developments in its partnership with Bluestar Medical [1] Company Developments - Bluestar Medical announced a collaboration with Baixinan for the Iberis™ multi-polar renal denervation (RDN) system, leveraging its platform capabilities and industry reputation to expand into international markets [1] - The Iberis™ RDN system has already been commercialized in Germany, Spain, and Italy, and has recently received approval for clinical use in Singapore [1] Market Potential - According to Zhi Shi Consulting, the annual market size for RDN in China is expected to exceed 10 billion RMB by 2032, indicating significant growth potential in this sector [1] - Huafu Securities highlighted that Baixinan's Iberis® RDN system is the only one globally approved for both transradial (TRA) and transfemoral access, showcasing a notable first-mover advantage [1] Strategic Partnerships - Baixinan has formed strategic collaborations with Yuanda Health and various international partners through Bluestar Medical, which is expected to accelerate its commercialization efforts [1] - The inclusion of the Iberis® RDN system in the healthcare insurance systems of Germany and France is anticipated to further enhance Baixinan's market position [1]
港股异动 | 百心安-B(02185)尾盘涨近15% RDN赛道迎来商业化放量新阶段 公司全球商业化有望加速